Seminar Briefing

Persson, U.

Seminar Briefing
November 2012

In this Seminar Briefing, Ulf Persson recounts Sweden’s experience with its approach to value based pricing (VBP). The model is a flexible approach that gives weight to cost-offsets outside the health sector and emphasises both encouraging innovation and enhancing access through such options as coverage with evidence development. He offers a series of examples to demonstrate how Sweden has addressed issues that any VBP system will face, including access to orphan drugs.

Riccaboni, M.

Seminar Briefing
June 2012

This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar.  It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry.  Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.

Donaldson, C.

Seminar Briefing
November 2011

Because health care resources always are scarce, decisions about what (and what not) to pay for cannot be avoided. Deciding how to value health and aspects of health care continue to be the subject of much debate. In this Briefing, Prof Donaldson takes a thorough look at the potential role of the willingess to pay (WTP) approach as a means for valuing the intangibles in health care. He examines whether more explicit monetary valuation of benefits, through elicitation of patients’ and the public’s willingness to pay, are not only useful, buy feasible and defensible in

Sharma, P.

Seminar Briefing
November 2011

Antibacterial drug resistance is a serious and growing worldwide problem that threatens our ability to cure traditionally treatable diseases and to successfully perform numerous surgical procedures that rely on antibacterials. The current situation is due primarily to two causes: inappropriate use in humans and animals and the decline in the development of new antibacterials, largely because of lower returns on investment in R&D.

Grabowski, H.G.

Seminar Briefing
January 2011

Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under a law passed in 2007. The PRV entitles the holder to priority review by the FDA of another drug of the bearer’s choice.  The Vouchers are transferable, i.e., not limited to use by the company that gained approval of the neglected-disease drug.  

Martin, B.

Seminar Briefing
December 2010

Professor Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) defines science policy research as ‘economic, policy, management and organisational studies of science, technology and innovation (STI) with a view to providing useful inputs to decision-makers concerned with policies for and the management of STI’.  The field is important because STI is important: it is a source of progress, a major contributor to the wealth of nations, provides the basis for new goods and services and for new capabilities, and contributes to changes in the quality of life and t

Sussex, J.

Seminar Briefing
August 2010

Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included representatives of the pharmaceutical industry, health technology assessment bodies and academic economists.

Sussex, J.

Seminar Briefing
December 2003

The purpose of the conference was to locate and promote the role of health economics in mental health policy in low and middle income countries. Health economists have a growing voice in health policy development. But just as it is only recently that mental health policy specifically has been highlighted on the global stage, with the WHO’s 2001 World Health Report, so too has the economics of mental health only comparatively recently started to claim attention on the global policy stage.

Sussex, J.

Seminar Briefing
December 2002

This briefing is based on the results of a seminar held in London on 30 May 2002. The seminar titled Building long term partnerships, was organised jointly by the Office of Health Economics and ACCA with the Future Healthcare Network of the NHS Confederation.

Locock, L. ed.

Seminar Briefing
October 1999

A number of important themes emerged, as well as some signals as to the leadership development needs of those charged with ensuring PCGs’ success.

They challenges they face are to:

Pages

Subscribe to RSS - Seminar Briefing